NCT03598582View on ClinicalTrials.gov

Biological Predictive Factors of Response to ESA in Low Risk MDS Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 1, 2013

Primary Completion Date

May 1, 2017

Study Completion Date

May 1, 2018

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Epoetin Zeta

"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."

All Listed Sponsors
lead

Association pour la recherche sur les Affections Malignes en Immunologie Sanguine

OTHER

NCT03598582 - Biological Predictive Factors of Response to ESA in Low Risk MDS Patients | Biotech Hunter | Biotech Hunter